{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:13:07Z","timestamp":1792098787335,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T00:00:00Z","timestamp":1512432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T00:00:00Z","timestamp":1512432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cholangiocarcinoma (CCA) represents a rare form of primary liver cancer with increasing incidence but dismal prognosis. Surgical treatment has remained the only potentially curative treatment option, but it remains unclear which patients benefit most from liver surgery, highlighting the need for new preoperative stratification strategies. In clinical routine, CA19-9 represents the most widely used tumor marker in CCA patients. However, data on the prognostic value of CA19-9 in CCA patients are limited and often inconclusive, mostly due to small cohort sizes. Here, we investigated the prognostic value of CA19-9 in comparison with other standard laboratory markers in a large cohort of CCA patients that underwent tumor resection. Of note, while CA19-9 and CEA were able to discriminate between CCA and healthy controls, CEA showed a higher accuracy for the differentiation between CCA and patients with primary sclerosing cholangitis (PSC) compared to CA19-9. Furthermore, patients with elevated levels of C-reactive protein (CRP), CA19-9 or CEA showed a significantly impaired survival in Kaplan-Meier curve analysis, but surprisingly, only CEA but not CA19-9 represented an independent predictor of survival in multivariate Cox-regression analysis. Our data suggest that CEA might help to identify CCA patients with an unfavourable prognosis after tumor resection.<\/jats:p>","DOI":"10.1038\/s41598-017-17175-7","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T11:43:37Z","timestamp":1511955817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-1161","authenticated-orcid":false,"given":"Sven H.","family":"Loosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Roderburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja L.","family":"Kauertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihael","family":"Vucur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne T.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Binneb\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom F.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lurje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzel","family":"Schoening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Longerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis H.","family":"Dejong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf P.","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"17175_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava, N. & Gores, G. J. Cholangiocarcinoma. Lancet \n                           383, 2168\u20132179 (2014).","journal-title":"Lancet"},{"key":"17175_CR2","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle, J. W. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. \n                           27, v28\u2013v37 (2016).","journal-title":"Ann. Oncol."},{"key":"17175_CR3","first-page":"21","volume":"1","author":"MC Bragazzi","year":"2011","unstructured":"Bragazzi, M. C. et al. Cholangiocarcinoma: Epidemiology and risk factors. Translational Gastrointestinal Cancer \n                           1, 21\u201332 (2011).","journal-title":"Translational Gastrointestinal Cancer"},{"key":"17175_CR4","doi-asserted-by":"publisher","first-page":"463-73","DOI":"10.1097\/00000658-199610000-00005","volume":"224","author":"A Nakeeb","year":"1996","unstructured":"Nakeeb, A. et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. \n                           224, 463-73\u20135 (1996).","journal-title":"Ann. Surg."},{"key":"17175_CR5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00268-009-9970-0","volume":"33","author":"A Guglielmi","year":"2009","unstructured":"Guglielmi, A. et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J. Surg. \n                           33, 1247\u201354 (2009).","journal-title":"World J. Surg."},{"key":"17175_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4251\/wjgo.v5.i7.147","volume":"5","author":"A Serrablo","year":"2013","unstructured":"Serrablo, A. & Tejedor, L. Outcome of surgical resection in Klatskin tumors. World J. Gastrointest. Oncol. \n                           5, 147\u201358 (2013).","journal-title":"World J. Gastrointest. Oncol."},{"key":"17175_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1478-3231.2010.02345.x","volume":"31","author":"W-R Matull","year":"2011","unstructured":"Matull, W.-R. et al. R0 but not R1\/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int. \n                           31, 99\u2013107 (2011).","journal-title":"Liver Int."},{"key":"17175_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00268-016-3551-9","volume":"40","author":"MJ Kang","year":"2016","unstructured":"Kang, M. J. et al. Actual Long-Term Survival Outcome of 403 Consecutive Patients with Hilar Cholangiocarcinoma. World J. Surg. \n                           40, 2451\u20139 (2016).","journal-title":"World J. Surg."},{"key":"17175_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/hpb.12441","volume":"17","author":"SM Weber","year":"2015","unstructured":"Weber, S. M. et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). \n                           17, 669\u201380 (2015).","journal-title":"HPB (Oxford)."},{"key":"17175_CR10","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11605-015-2854-8","volume":"19","author":"KE Poruk","year":"2015","unstructured":"Poruk, K. E., Pawlik, T. M. & Weiss, M. J. Perioperative Management of Hilar Cholangiocarcinoma. J. Gastrointest. Surg. \n                           19, 1889\u201399 (2015).","journal-title":"J. Gastrointest. Surg."},{"key":"17175_CR11","doi-asserted-by":"publisher","first-page":"657309","DOI":"10.1155\/2013\/657309","volume":"2013","author":"AT Ruys","year":"2013","unstructured":"Ruys, A. T., Busch, O. R., Rauws, E. A., Gouma, D. J. & van Gulik, T. M. Prognostic impact of preoperative imaging parameters on resectability of hilar cholangiocarcinoma. HPB Surg. \n                           2013, 657309 (2013).","journal-title":"HPB Surg."},{"key":"17175_CR12","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/ajg.2014.327","volume":"109","author":"R Chaiteerakij","year":"2014","unstructured":"Chaiteerakij, R. et al. A new clinically based staging system for perihilar cholangiocarcinoma. Am. J. Gastroenterol. \n                           109, 1881\u201390 (2014).","journal-title":"Am. J. Gastroenterol."},{"key":"17175_CR13","first-page":"105","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J. Gastrointest. Oncol. \n                           3, 105\u201319 (2012).","journal-title":"J. Gastrointest. Oncol."},{"key":"17175_CR14","first-page":"11683","volume":"8","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int. J. Clin. Exp. Med. \n                           8, 11683\u201391 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"17175_CR15","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.12659\/MSM.895040","volume":"21","author":"B Liang","year":"2015","unstructured":"Liang, B. et al. Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Med. Sci. Monit. \n                           21, 3555\u201363 (2015).","journal-title":"Med. Sci. Monit."},{"key":"17175_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3748\/wjg.v10.i3.427","volume":"10","author":"X-L Qin","year":"2004","unstructured":"Qin, X.-L. et al. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J. Gastroenterol. \n                           10, 427\u201332 (2004).","journal-title":"World J. Gastroenterol."},{"key":"17175_CR17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s11605-016-3180-5","volume":"20","author":"Y Kato","year":"2016","unstructured":"Kato, Y., Takahashi, S., Gotohda, N. & Konishi, M. Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer. J. Gastrointest. Surg. \n                           20, 1435\u201343 (2016).","journal-title":"J. Gastrointest. Surg."},{"key":"17175_CR18","first-page":"7890","volume":"7","author":"W-K Cai","year":"2014","unstructured":"Cai, W.-K. et al. Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int. J. Clin. Exp. Pathol. \n                           7, 7890\u20138 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"17175_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jgh.13059","volume":"31","author":"BS Lee","year":"2016","unstructured":"Lee, B. S. et al. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J. Gastroenterol. Hepatol. \n                           31, 493\u2013500 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"17175_CR20","first-page":"744","volume":"7","author":"M-S Lin","year":"2014","unstructured":"Lin, M.-S., Huang, J.-X. & Yu, H. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int. J. Clin. Exp. Med. \n                           7, 744\u201350 (2014).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"17175_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5152\/tjg.2014.6056","volume":"25","author":"AT Ince","year":"2014","unstructured":"Ince, A. T. et al. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions. Turk. J. Gastroenterol. \n                           25, 162\u20139 (2014).","journal-title":"Turk. J. Gastroenterol."},{"key":"17175_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopha.2016.12.064","volume":"87","author":"V Das","year":"2017","unstructured":"Das, V., Kalita, J. & Pal, M. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. Biomed. Pharmacother. \n                           87, 8\u201319 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"17175_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ijsu.2015.11.065","volume":"25","author":"CG S\u00f8rensen","year":"2016","unstructured":"S\u00f8rensen, C. G., Karlsson, W. K., Pommergaard, H.-C., Burcharth, J. & Rosenberg, J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence \u2013 A systematic review. Int. J. Surg. \n                           25, 134\u2013144 (2016).","journal-title":"Int. J. Surg."},{"key":"17175_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1155\/2013\/196412","volume":"34","author":"G Malaguarnera","year":"2013","unstructured":"Malaguarnera, G. et al. Serum markers of intrahepatic cholangiocarcinoma. Dis. Markers \n                           34, 219\u201328 (2013).","journal-title":"Dis. Markers"},{"key":"17175_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2827-7","volume":"16","author":"Z-Y Lin","year":"2016","unstructured":"Lin, Z.-Y. et al. Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels. BMC Cancer \n                           16, 792 (2016).","journal-title":"BMC Cancer"},{"key":"17175_CR26","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.3748\/wjg.v12.i34.5495","volume":"12","author":"T Gerhardt","year":"2006","unstructured":"Gerhardt, T. et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J. Gastroenterol. \n                           12, 5495\u2013500 (2006).","journal-title":"World J. Gastroenterol."},{"key":"17175_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jso.24381","volume":"114","author":"JR Bergquist","year":"2016","unstructured":"Bergquist, J. R. et al. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. J. Surg. Oncol. \n                           114, 475\u201382 (2016).","journal-title":"J. Surg. Oncol."},{"key":"17175_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1572-0241.2000.01685.x","volume":"95","author":"AH Patel","year":"2000","unstructured":"Patel, A. H., Harnois, D. M., Klee, G. G., LaRusso, N. F. & Gores, G. J. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. \n                           95, 204\u20137 (2000).","journal-title":"Am. J. Gastroenterol."},{"key":"17175_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1478-3231.1999.tb00083.x","volume":"19","author":"E Bj\u00f6rnsson","year":"1999","unstructured":"Bj\u00f6rnsson, E., Kilander, A. & Olsson, R. CA19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver \n                           19, 501\u20138 (1999).","journal-title":"Liver"},{"key":"17175_CR30","unstructured":"Wittekind, C., Gospodarowicz, M. K. & Sobin, L. H. UICC: TNM Classification of Malignant Tumors, 7th Edition. (Wiley-Blackwell, 2010)."},{"key":"17175_CR31","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s10620-012-2401-3","volume":"58","author":"PGK Venkatesh","year":"2013","unstructured":"Venkatesh, P. G. K., Navaneethan, U., Shen, B. & McCullough, A. J. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig. Dis. Sci. \n                           58, 850\u20137 (2013).","journal-title":"Dig. Dis. Sci."},{"key":"17175_CR32","first-page":"466","volume":"38","author":"C Bi","year":"2016","unstructured":"Bi, C. et al. [Analysis of the survival of 123 patients with intrahepatic cholangiocarcinoma after surgical resection]. Zhonghua Zhong Liu Za Zhi \n                           38, 466\u201371 (2016).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"17175_CR33","first-page":"5506","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Yang, H., Shen, C. & Luo, J. Cholangiocarcinoma: prognostic factors after surgical resection in China. Int. J. Clin. Exp. Med. \n                           8, 5506\u201312 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"17175_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.surge.2014.05.003","volume":"14","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Long-term outcome after surgical resection for cholangiocarcinoma and prognostic index value. Surgeon \n                           14, 38\u201343 (2016).","journal-title":"Surgeon"},{"key":"17175_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/jso.23666","volume":"110","author":"N Kondo","year":"2014","unstructured":"Kondo, N. et al. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J. Surg. Oncol. \n                           110, 422\u20139 (2014).","journal-title":"J. Surg. Oncol."},{"key":"17175_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2016.10.006","volume":"463","author":"C Sauzay","year":"2016","unstructured":"Sauzay, C. et al. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin. Chim. Acta \n                           463, 39\u201344 (2016).","journal-title":"Clin. Chim. Acta"},{"key":"17175_CR37","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","volume":"33","author":"T Patel","year":"2001","unstructured":"Patel, T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology \n                           33, 1353\u20137 (2001).","journal-title":"Hepatology"},{"key":"17175_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4253\/wjge.v8.i3.128","volume":"8","author":"D Viterbo","year":"2016","unstructured":"Viterbo, D., Gausman, V. & Gonda, T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J. Gastrointest. Endosc. \n                           8, 128\u201342 (2016).","journal-title":"World J. Gastrointest. Endosc."},{"key":"17175_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.biopha.2016.02.045","volume":"81","author":"J Hu","year":"2016","unstructured":"Hu, J. & Yin, B. Advances in biomarkers of biliary tract cancers. Biomed. Pharmacother\u2009=\u2009Biom\u00e9decine pharmacoth\u00e9rapie \n                           81, 128\u201335 (2016).","journal-title":"Biomed. Pharmacother.\u2009=\u2009Biom\u00e9decine pharmacoth\u00e9rapie"},{"key":"17175_CR40","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","volume":"234","author":"WR Jarnagin","year":"2001","unstructured":"Jarnagin, W. R. et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg \n                           234, 507\u2013509 (2001).","journal-title":"Ann Surg"},{"key":"17175_CR41","doi-asserted-by":"publisher","unstructured":"Nicholson, B. D. et al. in Cochrane Database of Systematic Reviews (ed. Nicholson, B. D.) CD011134, https:\/\/doi.org\/10.1002\/14651858.CD011134.pub2 (John Wiley & Sons, Ltd, 2015).","DOI":"10.1002\/14651858.CD011134.pub2"},{"key":"17175_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2559.1989.tb02186.x","volume":"14","author":"C Brumm","year":"1989","unstructured":"Brumm, C., Schulze, C., Charels, K., Morohoshi, T. & Kl\u00f6ppel, G. The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours. Histopathology \n                           14, 503\u201313 (1989).","journal-title":"Histopathology"},{"key":"17175_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1600-0676.1987.tb00334.x","volume":"7","author":"A Nonomura","year":"1987","unstructured":"Nonomura, A. et al. Immunohistochemical localization of ras p21 and carcinoembryonic antigens (CEA) in cholangiocarcinoma. Liver \n                           7, 142\u20138 (1987).","journal-title":"Liver"},{"key":"17175_CR44","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.surg.2015.10.027","volume":"159","author":"H Saito","year":"2016","unstructured":"Saito, H. et al. A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma. Surgery \n                           159, 842\u201351 (2016).","journal-title":"Surgery"},{"key":"17175_CR45","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cgh.2015.07.014","volume":"13","author":"A Wannhoff","year":"2015","unstructured":"Wannhoff, A. et al. Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis. Clin. Gastroenterol. Hepatol. \n                           13, 2372\u20132379 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"17175_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0988-4","volume":"19","author":"C Roderburg","year":"2015","unstructured":"Roderburg, C. et al. Persistently elevated osteopontin serum levels predict mortality in critically ill patients. Crit. Care \n                           19, 271 (2015).","journal-title":"Crit. Care"},{"key":"17175_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/cc10037","volume":"15","author":"A Koch","year":"2011","unstructured":"Koch, A. et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit. Care \n                           15, R63 (2011).","journal-title":"Crit. Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17175-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17175-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17175-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T15:13:25Z","timestamp":1671808405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17175-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,5]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["17175"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-17175-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,5]]},"assertion":[{"value":"30 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16975"}}